Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
56.93
+0.72 (1.28%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Royalty Pharma Market Cap
Royalty Pharma has a market cap or net worth of $32.73 billion as of October 9, 2026. It is the 760th most valuable company in the world and the 337th biggest in the United States. Its market cap has increased by 110.23% in one year.
Market Cap
32.73B
Enterprise Value
40.86B
1-Year Change
110.23%
Global Rank
Country Rank
#337 United States
Category
ChartMarket Cap Chart
Since June 16, 2020, Royalty Pharma's market cap has increased from $15.76B to $32.73B, an increase of 107.70%. That is a compound annual growth rate of 12.26%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 25.35B | 53.55% |
| Dec 31, 2025 | 16.51B | 45.66% |
| Dec 31, 2024 | 11.33B | -9.30% |
| Dec 29, 2023 | 12.50B | -28.31% |
| Dec 30, 2022 | 17.43B | 1.85% |
| Dec 31, 2021 | 17.12B | -11.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Jun 16, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| argenx SE | 51.01B |
| Revolution Medicines | 40.67B |
| BeOne Medicines AG | 40.30B |
| Alnylam Pharmaceuticals | 31.13B |
| Roivant Sciences | 25.60B |
| BioNTech SE | 24.36B |
| Incyte | 22.86B |
| Insmed | 21.97B |